Mr. D'Arcy Funfer reports
NDATALYZE CORP. ANNOUNCES APPOINTMENT OF A NEW PRESIDENT AND DIRECTOR, THE RESIGNATION OF A CURRENT DIRECTOR, AND STOCK OPTION GRANTS
Effective immediately, D'Arcy Funfer will become Ndatalyze Corp.'s president and chief executive officer. Jim Durward, the outgoing president and CEO, will stay on as chairman of the board of directors. Mr. Funfer will also succeed Gordon Crawford as a director, and the corporation thanks Mr. Crawford for his service and wishes him well in his endeavours.
Over the past six months, the corporation has been quietly developing its advanced athletic assessment platform (EpitomePD) and can now focus on the commercialization phase. EpitomePD can address multiple sports and other high human performance markets, with the initial focus being Hockey.
Mr. Funfer, the new president, states: "I'm grateful to Ndatalyze's board of directors for entrusting me with the role of president and CEO. What excites me about EpitomePD is its goal of helping individual amateur hockey players better understand how they are built so they can develop smarter. By bringing together insights into a player's mindset, genetic predispositions and environmental development, the platform helps players, families and coaches make more informed training decisions. I'm honoured to lead EpitomePD as we bring this approach to more players and hockey organizations across North America and beyond."
The corporation has granted an aggregate of 3.7 million stock options to its directors and officers, pursuant to the corporation's stock option plan, at an exercise price of five cents per common share
and expiring two years from the date of grant. The stock options are subject to a customary four-month hold period from the date of grant.
About Ndatalyze Corp.
Ndatalyze is a technology company focused on developing health and performance-related solutions through the application of artificial intelligence and biometric data analytics, including the Epitome sports performance platform.
We seek Safe Harbor.
© 2026 Canjex Publishing Ltd. All rights reserved.